Wangpu Xiongzhi, Yang Xiao, Zhao Jingkun, Lu Jiaoyang, Guan Shaopei, Lu Jun, Kovacevic Zaklina, Liu Wensheng, Mi Lan, Jin Runsen, Sun Jing, Yue Fei, Ma Junjun, Lu Aiguo, Richardson Des R, Wang Lishun, Zheng Minhua
Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Shanghai Minimally Invasive Surgery Center, Shanghai, 200025, China.
Oncotarget. 2015 Oct 20;6(32):33893-911. doi: 10.18632/oncotarget.5294.
N-myc downstream-regulated gene 1 (NDRG1), has been identified as an important metastasis suppressor for colorectal cancer (CRC). In this study, we investigated: (1) the effects of NDRG1 on CRC stemness and tumorigenesis; (2) the molecular mechanisms involved; and (3) the relationship between NDRG1 expression and colorectal cancer prognosis. Our investigation demonstrated that CRC cells with silenced NDRG1 showed more tumorigenic ability and stem cell-like properties, such as: colony and sphere formation, chemoresistance, cell invasion, high expression of CD44, and tumorigenicity in vivo. Moreover, NDRG1 silencing reduced β-catenin expression on the cell membrane, while increasing its nuclear expression. The anti-tumor activity of NDRG1 was demonstrated to be mediated by preventing β-catenin nuclear translocation, as silencing of this latter molecule could reverse the effects of silencing NDRG1 expression. NDRG1 expression was also demonstrated to be negatively correlated to CRC prognosis. In addition, there was a negative correlation between NDRG1 and nuclear β-catenin and also NDRG1 and CD44 expression in clinical CRC specimens. Taken together, our investigation demonstrates that the anti-metastatic activity of NDRG1 in CRC occurs through the down-regulation of nuclear β-catenin and suggests that NDRG1 is a significant therapeutic target.
N-myc下游调控基因1(NDRG1)已被确定为结直肠癌(CRC)的一种重要转移抑制因子。在本研究中,我们调查了:(1)NDRG1对CRC干性和肿瘤发生的影响;(2)其中涉及的分子机制;以及(3)NDRG1表达与结直肠癌预后的关系。我们的研究表明,NDRG1沉默的CRC细胞表现出更强的致瘤能力和干细胞样特性,如:集落和球体形成、化学抗性、细胞侵袭、CD44高表达以及体内致瘤性。此外,NDRG1沉默降低了细胞膜上β-连环蛋白的表达,同时增加了其核内表达。NDRG1的抗肿瘤活性被证明是通过阻止β-连环蛋白的核转位介导的,因为沉默该分子可以逆转沉默NDRG1表达的作用。NDRG1表达也被证明与CRC预后呈负相关。此外,在临床CRC标本中,NDRG1与核β-连环蛋白以及NDRG1与CD44表达之间存在负相关。综上所述,我们的研究表明NDRG1在CRC中的抗转移活性是通过下调核β-连环蛋白实现的,并表明NDRG1是一个重要的治疗靶点。